Ask a Fool! We Answer Your Healthcare Questions on Trials, Patents, and Pharmacy Retailers
If you've ever wondered why drugmakers run Phase I-II or II B clinical trials, how drugmakers like AbbVie (NYSE: ABBV) plan on keeping generic drugmakers at bay after their patents expire, or why pharmacy retailers like Walgreens Boots Alliance (NASDAQ: WBA) and CVS Health (NYSE: CVS) aren't making more money off aging baby boomers, you're not alone.
Listeners to The Motley Fool's Industry Focus: Healthcare podcast asked those exact questions, and in today's show, analyst Kristine Harjes and contributor Todd Campbell answer them. The two explain how interim clinical trials can save drugmakers money, how drugmakers use the court system protect billions of dollars in sales, and why falling generic drug prices are creating headwinds for retail pharmacy chains.
A full transcript follows the video.
Source: Fool.com
Walgreens Boots Alliance Inc. Aktie
Leichte Community-Abneigung: Walgreens Boots Alliance Inc. mit mehr Sell- als Buy-Einschätzungen.
Für Walgreens Boots Alliance Inc. ergibt sich ein positives Potenzial von 105.45%, obwohl das Kursziel von 30 € über dem aktuellen Kurs von 14.6 € liegt.
